Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features (Q46860354)
Jump to navigation
Jump to search
scientific article published in December 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features |
scientific article published in December 2007 |
Statements
1 reference
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features (English)
1 reference
Tait D Shanafelt
1 reference
Timothy G Call
1 reference
Clive S Zent
1 reference
Diane F Jelinek
1 reference
Susan M Schwager
1 reference
Neil E Kay
1 reference
Deborah A Bowen
1 reference
Greg D Jenkins
1 reference
Daniel L Van Dyke
1 reference
1 December 2007
1 reference
1 reference
48
1 reference
12
1 reference
2412-2417
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference